Enasinib 50 mg (Enasidenib)

Enasinib 50 mg (Enasidenib) – Targeted Therapy for Relapsed or Refractory AML

Enasinib 50 mg is a targeted oral oncology formulation used to treat patients diagnosed with acute myeloid leukemia (AML) who harbor specific IDH2 gene mutations. It belongs to a class of drugs known as IDH2 inhibitors, specifically designed to impede the abnormal function of the isocitrate dehydrogenase-2 enzyme.

This formulation, containing the active ingredient enasidenib, is an economical generic alternative to Idhifa. Enasinib 50 mg provides a more convenient and affordable option, ensuring patients globally can access precision oncology therapies without excessive financial burden.

Approved Uses and Scientific Mechanism

Indication: Who Is Prescribed Enasinib 50 mg?

Doctors prescribe Enasinib 50 mg specifically for the treatment of adult patients with relapsed or refractory AML (Acute Myeloid Leukemia) fostering IDH2 mutations, confirmed via an FDA-approved diagnostic test.

This therapy is typically used:

• • After the failure of at least one previous treatment regimen.

  • As part of a long-term personalized cancer treatment strategy.

  • For patients who are not candidates for intensive chemotherapy due to age or underlying health conditions.

How Enasinib 50 mg Works (Mechanism of Action)

Enasinib 50 mg works by inhibiting the activity of mutated IDH2 enzymes in cancer cells. Under normal conditions, IDH2 helps generate energy for cells. However, when mutated, it promotes cancer evolution by producing an atypical substance called 2-hydroxyglutarate (2-HG). High levels of 2-HG obstruct normal cell division, causing undeveloped white blood cells to build up in the bone marrow.

By blocking IDH2, the medication lowers the level of 2-HG, permitting leukemia cells to mature and die naturally. This targeted mechanism helps restore normal blood cell production and slows disease progression.

Dosage Recommendations and Administration Guidelines

The standard recommended dose for enasidenib is 100 mg once daily, taken at the same time each day, with or without food. As Enasinib is available in 50 mg tablets, your doctor will provide specific instructions on the number of tablets to take to achieve the required dosage.

• Duration: The span of treatment relies on the patient’s well-being and clinical response.

• Administration: Do not crush, chew, or split the tablet. Swallow whole with water.

• Missed Dose: If you miss a dose, follow your oncologist’s instructions. Do not double the dose to make up for a missed one.

• Monitoring: Constant blood tests are needed to observe reactions, complete blood counts (CBCs), and potential side effects.

Safety Profile, Precautions, and Contraindications

Who Should Not Use This Medication? (Contraindications)

Enasinib 50 mg is not suggested for:

• Persons allergic to enasidenib or any inactive ingredient in the composition.

• Women who are pregnant or breastfeeding.

• Patients with uncontrolled liver infection or acute hepatic damage.

• Those not confirmed to have an IDH2 mutation by genetic testing.

Common Side Effects

Most patients tolerate Enasinib 50 mg well, but some may experience side effects. Commonly reported reactions include:

• Nausea and Diarrhea

• Fatigue and Loss of appetite

• Elevated bilirubin levels

Important Warning: Differentiation Syndrome

A serious condition known as differentiation syndrome can occur. Signs include fever, shortness of breath, sudden weight gain, and fluid retention. This potentially serious condition must be treated instantly with corticosteroids and medical attention.

Drug Interactions

Patients must brief their doctor about all the drugs and supplements they are using. Some substances may affect how Enasinib 50 mg is metabolized, including:

• Strong CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin).

• Antifungal drugs and Anticonvulsants.

• Certain herbal supplements (like St. John’s wort).

• Grapefruit juice should be avoided as it may affect drug metabolism.

Manufacturer, Supplier, and Global Access

Manufacturer Information

Enasinib 50 mg is manufactured by Everest Pharmaceuticals Ltd, one of the leading drug manufacturers in Bangladesh. With WHO-GMP and ISO certifications, Everest ensures that its oncology products meet rigorous international quality standards, providing high-quality generic oncology medicines at affordable prices.

Your Trusted Global Supplier: Onus Pharma

Onus Pharma is the global supplier of Enasinib 50 mg, offering reliable sourcing, competitive pricing, and regulatory support. We work with hospitals, clinics, NGOs, and wholesalers across continents to ensure patients can obtain life-saving treatments on time.

Our logistics system supports:

• Cold-chain management

• Document authentication

• Custom clearance assistance

Access and Availability

Enasinib 50 mg is available to be shipped globally (except in countries with specific medication restrictions). Buyers must ensure they have a valid prescription, and compliance with local import laws is required. Onus Pharma currently supplies to over 30 countries in Asia, Africa, Latin America, and Eastern Europe.